Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled crossover study of DTX401 gene therapy in glycogen storage disease type Ia
NL-OMON56166Phase 3Recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- May 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of pariglasgene brecaparvovec in glycogen storage disease type 1a (GSD1a), sponsored by Ultragenyx Pharmaceutical Inc.. Started May 2022; status: recruiting.
02
Drugs
pariglasgene brecaparvovec
03
Conditions
glycogen storage disease type 1a (GSD1a)
Beyond the preview
Go deeper on NL-OMON56166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56166.